

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Current progress and future perspectives in the... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-1024/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-1024" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents" />
    
            <meta name="og:title" content="F1000Research Article: Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.">
            <meta name="og:description" content="Read the latest article version by Jung-Eun Park, David Hymel, Terrence R. Burke, Jr., Kyung S. Lee, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12303">
            <meta name="article-id" content="11398">
            <meta name="dc.title" content="Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents">
            <meta name="dc.description" content="Although significant levels of side effects are often associated with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics. With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression. As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery. To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clinical trials. Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics.">
            <meta name="dc.subject" content="anti-cancer therapeutics, anti-mitotic agents, mitotic targets, polo-like kinase 1, Plk1, anti-Plk1 agents">
            <meta name="dc.creator" content="Park, Jung-Eun">
            <meta name="dc.creator" content="Hymel, David">
            <meta name="dc.creator" content="Burke, Jr., Terrence R.">
            <meta name="dc.creator" content="Lee, Kyung S.">
            <meta name="dc.date" content="2017/06/29">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11398.1">
            <meta name="dc.source" content="F1000Research 2017 6:1024">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="anti-cancer therapeutics">
            <meta name="prism.keyword" content="anti-mitotic agents">
            <meta name="prism.keyword" content="mitotic targets">
            <meta name="prism.keyword" content="polo-like kinase 1">
            <meta name="prism.keyword" content="Plk1">
            <meta name="prism.keyword" content="anti-Plk1 agents">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/06/29">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="1024">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11398.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-1024">
            <meta name="citation_title" content="Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents">
            <meta name="citation_abstract" content="Although significant levels of side effects are often associated with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics. With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression. As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery. To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clinical trials. Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics.">
            <meta name="citation_description" content="Although significant levels of side effects are often associated with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics. With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression. As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery. To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clinical trials. Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics.">
            <meta name="citation_keywords" content="anti-cancer therapeutics, anti-mitotic agents, mitotic targets, polo-like kinase 1, Plk1, anti-Plk1 agents">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jung-Eun Park">
            <meta name="citation_author_institution" content="Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA">
            <meta name="citation_author" content="David Hymel">
            <meta name="citation_author_institution" content="Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, 21702, USA">
            <meta name="citation_author" content="Terrence R. Burke, Jr.">
            <meta name="citation_author_institution" content="Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, 21702, USA">
            <meta name="citation_author" content="Kyung S. Lee">
            <meta name="citation_author_institution" content="Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA">
            <meta name="citation_publication_date" content="2017/06/29">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="1024">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11398.1">
            <meta name="citation_firstpage" content="1024">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-1024/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-1024.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12303 /> <input type=hidden id=articleId name=articleId value=11398 /> <input type=hidden id=xmlUrl value="/articles/6-1024/v1/xml"/> <input type=hidden id=xmlFileName value="-6-1024-v1.xml"> <input type=hidden id=article_uuid value=aa983cb4-792d-408a-8467-383ca18cb772 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11398.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11398.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-1024"
  },
  "headline": "Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents",
  "datePublished": "2017-06-29T13:56:39",
  "dateModified": "2017-06-29T13:56:39",
  "author": [
    {
      "@type": "Person",
      "name": "Jung-Eun Park"
    },    {
      "@type": "Person",
      "name": "David Hymel"
    },    {
      "@type": "Person",
      "name": "Terrence R. Burke, Jr."
    },    {
      "@type": "Person",
      "name": "Kyung S. Lee"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Although significant levels of side effects are often associated with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics. With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression. As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery. To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clinical trials. Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-1024.html",
            "name": "Current progress and future perspectives in the development of anti-polo-like..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Current progress and future perspectives in the development of anti-polo-like... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12303 data-id=11398 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11398.1" data-recommended="" data-doi="10.12688/f1000research.11398.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-1024/v1/pdf?article_uuid=aa983cb4-792d-408a-8467-383ca18cb772" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11398-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11398-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11398-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Park JE, Hymel D, Burke, Jr. TR and Lee KS. Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1024 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11398.1" target=_blank>https://doi.org/10.12688/f1000research.11398.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11398-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11398 id=track-article-signin-11398 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11398?target=/articles/6-1024.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12303 /> <input name=articleId type=hidden value=11398 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents</h1><span class=other-info> [version 1; peer review: 4 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Jung-Eun Park<sup>1</sup>,&nbsp;</span><span class="">David Hymel<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:burkete@helix.nih.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Terrence R. Burke, Jr.</span></a><sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:kyunglee@mail.nih.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Kyung S. Lee</span></a><a href="https://orcid.org/0000-0001-8326-7162" target=_blank id=author-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-8326-7162</div><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Jung-Eun Park<sup>1</sup>,&nbsp;</span><span class="">David Hymel<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:burkete@helix.nih.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Terrence R. Burke, Jr.</span></a><sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:kyunglee@mail.nih.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Kyung S. Lee</span></a><a href="http://orcid.org/0000-0001-8326-7162" target=_blank id=mauthor-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-8326-7162</div><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 29 Jun 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11398.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA<br/> <sup>2</sup> Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, 21702, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=21914-21821></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=21918-23909></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=21916-23910></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=21917-23911></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Although significant levels of side effects are often associated with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics. With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression. As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery. To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clinical trials. Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> anti-cancer therapeutics, anti-mitotic agents, mitotic targets, polo-like kinase 1, Plk1, anti-Plk1 agents </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Terrence R. Burke, Jr. (<a href="mailto:burkete@helix.nih.gov">burkete@helix.nih.gov</a>) <br> Kyung S. Lee (<a href="mailto:kyunglee@mail.nih.gov">kyunglee@mail.nih.gov</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Terrence R. Burke, Jr., Kyung S. Lee </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported in part by the Intramural Research Program of the National Institutes of Health (NIH) National Cancer Institute (NCI) (K.S.L. and T.R.B). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Park JE <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Park JE, Hymel D, Burke, Jr. TR and Lee KS. Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1024 (<a href="https://doi.org/10.12688/f1000research.11398.1" target=_blank>https://doi.org/10.12688/f1000research.11398.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 29 Jun 2017, <b>6</b>(F1000 Faculty Rev):1024 (<a href="https://doi.org/10.12688/f1000research.11398.1" target=_blank>https://doi.org/10.12688/f1000research.11398.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 29 Jun 2017, <b>6</b>(F1000 Faculty Rev):1024 (<a href="https://doi.org/10.12688/f1000research.11398.1" target=_blank>https://doi.org/10.12688/f1000research.11398.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d19269e225>Introduction</h2><p class="" id=d19269e228>For several decades, anti-microtubule (MT) drugs such as taxanes and vinca alkaloids have been effectively used against a wide range of cancers, including solid and hematological malignancies<sup><a href="#ref-1">1</a></sup>. However, one of the major shortcomings of these MT-targeting agents has been severe and dose-limiting side effects that arise as the consequence of indiscriminately disrupting widespread MT functions, not only in actively dividing mitotic cells but also in non-dividing interphase cells. Thus, over the past decade, a high level of interest has been drawn to targeting a variety of mitosis-specific proteins in order to develop agents that can specifically disrupt the mitotic progression of highly proliferative cancer cells. These proteins include protein kinases (polo-like kinase 1 [Plk1]<sup><a href="#ref-2">2</a></sup> and Aurora A<sup><a href="#ref-3">3</a></sup>), motor proteins (CENP-E<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup> and Eg5<sup><a href="#ref-6">6</a></sup>), DNA-damage checkpoint proteins (Chk1 and Chk2<sup><a href="#ref-7">7</a></sup>), and components of the ubiquitin proteasome pathway (APC/Cdc20 and the proteasome<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>). Among these endeavors, anti-Plk1 drug discovery has reached an advanced stage of development that merits reflection on its progress. In this short review, we will summarize recent advances and future directions toward developing therapeutics against one of the most appealing anti-cancer drug targets, Plk1.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19269e269>Plk1 as an anti-mitotic target</h2><p class="" id=d19269e272>Plk1 belongs to the polo subfamily of Ser/Thr protein kinases (collectively, Plks) and plays a key role at multiple stages of mitotic progression<sup><a href="#ref-10">10</a></sup>. Plk1 is composed of the <i>N</i>-terminal catalytic domain and the <i>C</i>-terminal non-catalytic polo-box domain (PBD) (<a href="#f1">Figure 1</a>). The cooperative action of these two domains is critical for Plk1 to regulate diverse mitotic processes<sup><a href="#ref-11">11</a></sup>. Not surprisingly, Plk1 is overexpressed in a wide spectrum of human cancers<sup><a href="#ref-12">12</a></sup>, and its overexpression is thought to promote genomic instability and tumorigenesis<sup><a href="#ref-13">13</a>–<a href="#ref-15">15</a></sup>. In addition, upregulated Plk1 activity appears to be closely associated with the aggressiveness and poor prognosis of these cancers<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. Other studies have shown that various cancer cells—but not their isogenic normal cells—are addicted to Plk1 overexpression for their viability<sup><a href="#ref-18">18</a>–<a href="#ref-20">20</a></sup>. Since reversing addicted protein functions has proven to be an attractive strategy to selectively kill cancer cells<sup><a href="#ref-18">18</a>,<a href="#ref-21">21</a>–<a href="#ref-23">23</a></sup>, addiction to overexpressed Plk1 exacerbates the vulnerability of cancer cells to Plk1 interrogation. Thus, targeting Plk1 may permit the induction of cancer-cell-selective mitotic block and apoptotic cell death in Plk1-addicted cancers<sup><a href="#ref-24">24</a></sup>. Because human cancers are frequently slow growing, inhibiting a cancer-addicted target, such as Plk1, could be particularly effective in achieving the full therapeutic potential of an anti-mitotic agent.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure1.gif"><img alt="ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure1.gif"></a><div class=caption><h3>Figure 1. Schematic diagram of human polo-like kinase 1 (Plk1).</h3><p id=d19269e342>The numbers indicate the positions of the amino acid residues in human Plk1.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19269e352>Promising Plk1 ATP-competitive inhibitors and their limitations</h2><p class="" id=d19269e355>Targeting the catalytic activity of a protein kinase has been the predominant method of generating kinase inhibitors. Accordingly, a large number of ATP-competitive inhibitors directed against the catalytic activity of Plk1 have been developed and tested under various preclinical and clinical settings<sup><a href="#ref-24">24</a></sup> (<a href="#f2">Figure 2</a>). Among them, volasertib (a dihydropteridinone derivative; Boehringer Ingelheim) is widely considered the most advanced inhibitor in this class, exhibiting potent anti-tumor activities in multiple nude mouse xenograft models<sup><a href="#ref-25">25</a></sup>. Volasertib has also shown significant clinical efficacies against advanced solid and hematological cancers in phase I/II clinical trials<sup><a href="#ref-26">26</a>–<a href="#ref-30">30</a></sup>. However, the initial outcome of its phase III clinical trials, performed with a cohort of elderly acute myeloid leukemia patients, turned out to be less than satisfactory (the 21st Annual Congress of the European Hematology Association, 2016). In addition, several other ATP-competitive inhibitors, such as GSK461364 (a thiophene derivative; GlaxoSmithKline)<sup><a href="#ref-31">31</a></sup>, MLN0905 (a benzolactam derivative; Millennium)<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>, RO3280 (a pyrimidodiazepine derivative; Roche)<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>, NMS-P937 (a pyrazoloquinazoline derivative; Nerviano)<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>, and TAK-960 (a 2-aryl pyrimidodiazepinone derivative; Takeda)<sup><a href="#ref-38">38</a></sup> have shown only limited efficacy with more-than-acceptable dose-limiting toxicity in diverse preclinical/clinical trials. Dose-limiting toxicity arises mainly from non-specific activity of the inhibitors<sup><a href="#ref-39">39</a></sup>. In fact, one of the common problems associated with the currently available Plk1 ATP-competitive inhibitors is their low degree of selectivity against other kinases<sup><a href="#ref-24">24</a></sup>, including two that are closely related, Plk2 and Plk3, with possible tumor-suppressor function<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>. Therefore, improving Plk1 specificity is likely one of the most pressing concerns to address in order to accomplish better clinical outcomes with fewer toxicological problems.</p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure2.gif"><img alt="ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure2.gif"></a><div class=caption><h3>Figure 2. The structures of polo-like kinase 1 (Plk1) catalytic domain inhibitors.</h3><p id=d19269e432>Only widely studied inhibitors are shown.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19269e442>Future strategies to conquer current obstacles</h2><p class="" id=d19269e445>Generating ATP-competitive inhibitors aimed at inhibiting the catalytic activity of a protein kinase is a widely used approach, in part, because isolating small molecules that block the catalytic activity of a kinase is relatively straightforward. However, owing to the highly conserved nature of the ATP-binding pocket, a large fraction of this class of inhibitors show a significant level of cross-reactivity with various other kinases<sup><a href="#ref-39">39</a></sup>. Therefore, for a given kinase, having a better understanding of the exact nature of the ATP-binding site (and its neighboring interaction pockets, if they exist) could be crucial for overcoming lack of specificity associated with non-allosteric ATP-competitive inhibitors.</p><div class=section><a name=d19269e452 class=n-a></a><h3 class=section-title>Improving specificity through structure-assisted optimization</h3><p class="" id=d19269e457>Further development of Plk1 ATP-competitive inhibitors can be achieved through structure-guided medicinal chemistry targeting unique residues lining the ATP-binding pocket. Comparative analyses of the X-ray co-crystal structures of the catalytic domains of Plk1–3 revealed that the overall shapes of their ATP-binding pockets are similar, and the residues forming the pockets are mostly analogous to one another. Nevertheless, both F58 and R134 residues are unique to Plk1, whereas R57, L132, and R136 residues found in Plk1 and one of Plk2 and Plk3 ATP-binding pockets are semi-specific to Plk1<sup><a href="#ref-24">24</a></sup> (<a href="#f3">Figure 3</a>). These observations suggest that there may still be explorable chemical space, which can be exploited to further increase Plk1-binding specificity. Notably, volasertib and its parental dihydropteridinone derivative, BI 2536<sup><a href="#ref-42">42</a></sup>, do not interact with the Plk1-specific F58 and R134 residues but are in contact with the semi-specific R57, L132, and R136 residues and other neighboring residues (C67, L132, and F183) that are somewhat selective against non-Plks (<a href="#f3">Figure 3</a>). This finding explains in part why they exhibit a high level (~100–1,000-fold) of selectivity against other kinases but show less discriminatory activity against Plk1–3 (IC<sub>50</sub> values of 0.83, 5, and 56 nM for Plk1, Plk2, and Plk3, respectively)<sup><a href="#ref-25">25</a>,<a href="#ref-43">43</a></sup>.</p><div class="fig panel clearfix"><a name=f3 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure3.gif"><img alt="ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure3.gif"></a><div class=caption><h3>Figure 3. The binding modes of ADP (left panel, PDB: 3D5W) and volasertib (right panel, PDB: 3FC2) to the catalytic domain of polo-like kinase 1 (Plk1).</h3><p id=d19269e495>Ligand-binding regions that are important for achieving kinase selectivity are shown as colored surfaces. Region I is located near the conserved Asp-Phe-Gly (DFG) motif, which is important in the design of certain allosteric inhibitors. Region II is near the hinge region, and region III is a relatively hydrophobic pocket below the adenine-binding site. Compared to Plk2 and Plk3, residues that are specific (green) or semi-specific (red) to Plk1 are labeled. Notably, the aryl-methoxy group in region II (near L132 of the hinge region) is used to produce moderate selectivity for Plk1 against other Plks<sup><a href="#ref-44">44</a></sup>.</p></div></div><p class="" id=d19269e506>As noted above, one of the few differences between the ATP-binding pockets of Plk1 and Plk2 occurs near the hinge region (region II in <a href="#f3">Figure 3</a>), where L132 of Plk1 corresponds to Y161 in Plk2. This difference has been exploited to generate inhibitors that demonstrate ~1,000-fold selectivity for Plk2 versus Plk1<sup><a href="#ref-44">44</a></sup>. Such work highlights what can be achieved using structure-based drug design to take advantage of small differences in protein-binding sites. An additional effort to target the Plk1-specific F58 and R134 residues that lie at the mouth of the core ATP-binding pocket (<a href="#f3">Figure 3</a>) could lead to inhibitors with improved selectivity against other Plks. The generation of isoform-selective inhibitors is critically important to elucidate the biological roles of each individual Plk isoform, along with determining the importance of isoform selectivity in preventing the currently observed dose-limiting toxicities. Insights derived from such studies could further reveal the potential therapeutic value of targeting the catalytic domain of Plk1.</p></div><div class=section><a name=d19269e520 class=n-a></a><h3 class=section-title>Developing allosteric inhibitors</h3><p class="" id=d19269e525>To ensure high selectivity, ATP-competitive small molecules must be designed to maximally engage in receptor-ligand interactions or sterically fill unoccupied space within defined binding pockets. In addition, because allosteric sites are generally less conserved than orthosteric sites, developing strategies to target allosteric sites, if available, can be potentially very useful in deriving specific inhibitors against a target. Close examination of the co-crystal structures of the Plk1 catalytic domain in complex with either ADP or volasertib reveals three ligand-binding regions (regions I, II, and III) that are important for achieving kinase selectivity (<a href="#f3">Figure 3</a>). Volasertib appears to utilize each of these orthosteric binding regions to achieve selectivity against most clinically important kinases. It is noteworthy that the region I located near the conserved Asp-Phe-Gly (DFG) motif contains a shallow space that could be potentially utilized to further improve the drug–target interaction. Interestingly, a dimethoxybenzeneethanamine derivative, SBE13, is suggested to bind to Plk1 in its “DFG-out” conformation and inhibit the enzyme’s catalytic activity with outstanding specificity<sup><a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>. An allosteric hydrophobic pocket generated in the catalytically inactive, DFG-out conformation of many Tyr kinases and, less frequently, Ser/Thr kinases has been successfully targeted to improve the selectivity of an inhibitor<sup><a href="#ref-47">47</a>–<a href="#ref-49">49</a></sup>. However, no structural information is yet available to verify whether Plk1 can indeed embrace a DFG-out conformation and generate an allosteric hydrophobic pocket that potentially allows an ATP-competitive inhibitor to trap the enzyme in a catalytically inactive state.</p><p class="" id=d19269e545>Another potentially appealing strategy toward achieving target-specific allosteric inhibition of Plk1 could be to block its essential substrate-binding interface. In principle, this may be approached by understanding the nature of the Plk1-substrate binding interactions that are critical for proper mitotic progression. ON01910, a substituted benzyl styryl sulfone, was initially reported as a non-ATP-competitive inhibitor of Plk1 that was thought to interfere with the substrate-binding site<sup><a href="#ref-50">50</a></sup>. However, subsequent studies showed that it possesses rather poor anti-Plk1 activity and specificity and inhibits multiple kinases<sup><a href="#ref-43">43</a>,<a href="#ref-51">51</a>–<a href="#ref-53">53</a></sup>. In a broad sense, the anti-PBD agents described below can be classified as target-specific allosteric inhibitors, which inhibit Plk1 function by binding to a specific site distant from the ATP-binding pocket.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19269e566>The PBD as an alternative target for anti-Plk1 drug discovery</h2><p class="" id=d19269e569>The PBD is a functionally essential domain that binds to the enzyme’s physiological substrates and mediates the <i>cis-</i>acting phosphorylation of bound substrates by the <i>N</i>-terminal catalytic domain<sup><a href="#ref-54">54</a></sup>. A large body of evidence suggests that the Plk1 PBD contains a well-defined protein–protein interaction (PPI) pocket that can be inhibited by short peptides or peptide mimetics<sup><a href="#ref-24">24</a></sup>. Intriguingly, inhibition of Plk1 PBD function alone is sufficient for effectively imposing mitotic arrest and apoptotic cell death in cancer cells but not in normal cells<sup><a href="#ref-20">20</a></sup>. This suggests that targeting the PBD may serve as a promising alternative for developing anti-Plk1 therapeutics. It should be noted, however, that not all of Plk1’s substrates require a prior interaction with the PBD before being phosphorylated by its <i>N</i>-terminal catalytic domain<sup><a href="#ref-54">54</a></sup>. Therefore, inhibiting PBD function represents a target-restricted strategy that is designed to antagonize a subset of Plk1 functions dysregulated in cancer<sup><a href="#ref-24">24</a>,<a href="#ref-54">54</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19269e609>Advantages of targeting the Plk1 PBD</h2><p class="" id=d19269e612>Unlike ATP-competitive inhibitors, whose specificities must be obtained against more than 500 other cellular kinases<sup><a href="#ref-39">39</a></sup>, PBD inhibitors target a structurally unique domain found in only four proteins (Plk1−3 and Plk5)<sup><a href="#ref-24">24</a></sup>. This greatly diminishes the likelihood of facing unwanted non-specific cross-reactivities. Another potential advantage of targeting the PBD is that while ATP-competitive inhibitors can abrogate all Plk1-dependent biochemical processes indiscriminately in both cancer and normal cells, PBD inhibitors interfere in only a subset of Plk1 functions that require a PBD-mediated biochemical step. Furthermore, since the Plk1 PBD can interact with a variety of structurally diverse phosphoepitope-containing proteins<sup><a href="#ref-54">54</a></sup>, it is reasonable to speculate that anti-PBD agents could potentially be optimized so that they selectively inhibit a subset of PBD-dependent interactions, which are enriched in biochemically rewired, Plk1-addicted cancer cells<sup><a href="#ref-24">24</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19269e634>Current status on the development of anti-Plk1 PBD agents</h2><div class=section><a name=d19269e637 class=n-a></a><h3 class=section-title>Peptidomimetics</h3><p class="" id=d19269e642>Since the initial discovery of a pentameric p-Thr-containing peptide, PLHSpT, as a specific Plk1 PBD-binding ligand<sup><a href="#ref-55">55</a></sup>, several high-affinity peptide-derived inhibitors, including 4j (<a href="#f4">Figure 4</a>), have been generated<sup><a href="#ref-56">56</a>–<a href="#ref-58">58</a></sup>. These efforts have revealed that three distinct structural elements are critical for achieving high affinity and specific binding to the Plk1 PBD (<a href="#f5">Figure 5</a>). These are 1) a phosphoepitope-recognition pocket containing two basic residues (His538 and Lys540), which binds to Ser-Xxx motifs, where Xxx is p-Thr (or several-fold lower-affinity p-Ser) or a suitable anionic mimetic<sup><a href="#ref-55">55</a>,<a href="#ref-59">59</a></sup>, 2) an adjoining Pro-binding region that engages portions of the bound ligand <i>N</i>-proximal to the Ser-p-Thr dipeptide motif<sup><a href="#ref-55">55</a></sup>, and 3) a hydrophobic channel, which is capable of boosting the binding affinity ~500–1,000-fold without compromising Plk1 PBD specificity<sup><a href="#ref-56">56</a>–<a href="#ref-59">59</a></sup>. However, despite the fact that these peptide-based inhibitors exhibit extremely high affinity and specificity <i>in vitro</i>, their utility in cellular contexts is greatly decreased by poor membrane permeability and limited bioavailability. Efforts to increase cellular uptake have been directed at the reduction of anionic charge through charge masking and prodrug protection<sup><a href="#ref-60">60</a></sup>, macrocyclization<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>, and reducing peptide character<sup><a href="#ref-63">63</a></sup>.</p><div class="fig panel clearfix"><a name=f4 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure4.gif"><img alt="ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure4.gif"></a><div class=caption><h3>Figure 4. The structures of peptidomimetic and small molecule polo-box domain (PBD) inhibitors.</h3></div></div><div class="fig panel clearfix"><a name=f5 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure5.gif"><img alt="ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure5.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12303/ef21a382-ad67-4f92-b31f-bd26ecfe9879_figure5.gif"></a><div class=caption><h3>Figure 5. The structural model of polo-box domain (PBD) in complex with 4j.</h3><p id=d19269e727>The X-ray cocrystal structure of the PBD + 4j complex (PDB: 3RQ7) shows a “Y-shaped” binding pocket composed of three discrete but interlinked binding modules—namely, a p-Thr/p-Ser-binding module (violet), a Pro-binding module (yellow), and a hydrophobic channel (green). Residues highlighted in red are specific to Plk1 PBD. Inhibitors designed to bind to more than one of the three binding modules could possess a superior binding specificity because of the specific requirement of the shape and geometrical arrangement of their binding moieties (see text for details).</p></div></div></div><div class=section><a name=d19269e735 class=n-a></a><h3 class=section-title>Small molecule inhibitors</h3><p class="" id=d19269e740>Paralleling the development of peptidomimetics as described above are efforts to generate anti-Plk1 PBD agents that have yielded a wide range of small molecule inhibitors, including thymoquinone (TQ) and poloxin<sup><a href="#ref-64">64</a></sup>, poloxipan<sup><a href="#ref-65">65</a></sup>, purpurogallin (PPG)<sup><a href="#ref-66">66</a></sup>, T521<sup><a href="#ref-67">67</a></sup>, Cpd161<sup><a href="#ref-68">68</a></sup>, and (−)-epigallocatechin<sup><a href="#ref-69">69</a></sup> (<a href="#f4">Figure 4</a>). As expected, if they interfered with the function of Plk1 PBD, these inhibitors induce mitotic block and apoptotic cell death, at least at the cultured cell level. While X-ray crystallographic data suggested the binding nature of how TQ and its analogue poloxime bound to the p-Thr/p-Ser-binding module<sup><a href="#ref-70">70</a></sup>, the assignment of these ligands within the phosphoepitope-recognition module appears to be disputable because of the poor resolution of the reported crystal structures. In addition, whether TQ and poloxin can be used as a template for structure-assisted drug design and hit-to-lead optimization remains in doubt because of their low Plk1 PBD specificity and non-specific alkylating activity with other cellular proteins<sup><a href="#ref-68">68</a>,<a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>. Indeed, covalent protein reactivity and other chemotypes, such as polyhydroxylated aromatic compounds (e.g. PPG), are thought to be some of the common artifacts that lead to the isolation of pan assay interference compounds (PAINS)<sup><a href="#ref-73">73</a></sup> (as discussed in depth in a recent review<sup><a href="#ref-74">74</a></sup>).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19269e797>Future directions in anti-Plk1 PBD drug discovery</h2><div class=section><a name=d19269e800 class=n-a></a><h3 class=section-title>Multidirectional approaches to identify a lead with druggable properties</h3><p class="" id=d19269e805>Even though currently available peptide-derived and small molecule inhibitors have provided valuable information in understanding the nature of Plk1 PBD-dependent interactions and their cellular functions, it remains uncertain whether they can be used as leads for developing anti-PBD agents. Therefore, while these inhibitors are being further developed, additional endeavors could be considered in parallel in the hope of generating a new class of inhibitors with more druggable properties. Identifying promising leads possessing outstanding biochemical selectivity (i.e. specificity and affinity) and druggable physicochemical properties (e.g. solubility, bioavailability, chemical functionality, etc.) will likely be a critical step for successful lead optimization and ultimate discovery of anti-Plk1 PBD therapeutic agents.</p></div><div class=section><a name=d19269e809 class=n-a></a><h3 class=section-title>Exploiting the shape and geometrical arrangement of three adjacent binding modules of the Plk1 PBD-binding pocket to achieve high specificity</h3><p class="" id=d19269e814>Now it is clear that, unlike the nondescript nature of many PPI surfaces, the Plk1 PBD furnishes a well-defined binding interface that may make it more amenable for structure-based drug discovery. Accumulated data show that the affinity and specificity of Plk1 PBD binding are dependent on the ability of a ligand to interact with three adjacently placed but biochemically distinct binding modules<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup> that collectively form a “Y-shaped” binding pocket (reviewed in Lee <i>et al</i>.<sup><a href="#ref-24">24</a></sup>) (<a href="#f5">Figure 5</a>). Future anti-Plk1 PBD drug discovery could take advantage of the Y-shaped interaction interface, so that ligands are optimized as three discrete but interconnected binding-module platforms.</p><p class="" id=d19269e834>Recent work has demonstrated that suitably designed p-Thr mimetic derivatives optimized for the phosphoepitope-recognition module can achieve several-fold enhancement in PBD-binding affinity<sup><a href="#ref-75">75</a></sup>. In addition, structural elaboration of hydrophobic channel-binding functionality and improvement of the interactions with Plk1-specific residues found in the surroundings of the hydrophobic channel have significantly increased overall ligand affinity and selectivity<sup><a href="#ref-76">76</a>,<a href="#ref-77">77</a></sup>. These findings suggest that the binding affinity and specificity of each of the three binding modules are determined independently of one another. Since a ligand capable of simultaneously binding to two or more binding modules must additionally conform to the exact geometrical arrangement of these modules, anti-Plk1 PBD agents generated through the Y-shaped, three-binding-module platform (<a href="#f5">Figure 5</a>) may likely possess uncommon physical shapes and chemical properties that may allow them to reach a high level of specificity. Multiple modular bindings discussed here may also help diminish the probability of developing drug resistance.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d19269e855>Concluding remarks</h2><p class="" id=d19269e858>Given the significant level of side effects associated with conventional MT-targeting anticancer therapeutics, developing an inhibitor against a mitosis-specific and cancer-cell-addicted target such as Plk1 may represent a promising strategy for the generation of a cancer-cell-specific therapeutic agent. One of the unique molecular features of Plk1 is that it offers, within one molecule, two independent drug targets—the <i>N</i>-terminal catalytic domain and the <i>C</i>-terminal PBD. The primary challenge facing currently available ATP-competitive inhibitors of Plk1 appears to be their dose-limiting toxicities. Although this hurdle can be conquered in principle by improving specificity or generating potentially more specific allosteric inhibitors as discussed above, considering extensive efforts made to date, this advancement may not be easily accomplished unless a breakthrough occurs. In this regard, it is quite intriguing to define the PBD as an alternative target for anti-Plk1 drug discovery. In addition to the superb binding specificity that PPI inhibitors can bring, Plk1 PBD inhibitors can provide an opportunity to selectively interfere with cancer-cell-enriched Plk1 PBD-binding targets. If developed, Plk1 PBD inhibitors with superior specificity can be used not only as a single therapeutic agent but also as an agent easily amenable for combination therapy with other anti-cancer therapeutics.</p><p class="" id=d19269e867>Significantly, the use of multiple inhibitors targeting different regions within one molecule is considered an effective way to eliminate drug resistance and to diminish the side effects of a high dose of a single agent. Therefore, using a Plk1 PBD inhibitor in combination with an ATP-competitive inhibitor, such as volasertib, could present a great treatment regimen that may achieve the maximum drug efficacy of both inhibitors while keeping volasertib at the highest acceptable dose that does not cause nonspecific cytotoxicity. Considering the success of anti-mitotic therapeutics and the remarkable advantages of targeting Plk1, there is ample reason to believe that further developing anti-Plk1 therapeutics may prove to be a worthwhile endeavor in the fight against cancer.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d19269e1 class=n-a></a><h2 class=main-title id=d19513>Author contributions</h2><p class=metadata-entry><a name=d19269e142 class=n-a></a><p id=d19269e144> K.S.L., T.R.B., J.E.P., and D.H. wrote the manuscript, and T.R.B., J.E.P., and D.H. generated figures.</p></p></div><div class=back-section><a name=d19269e1 class=n-a></a><h2 class=main-title id=d19517>Competing interests</h2><p class=metadata-entry><a name=d19269e148 class=n-a></a><p id=d19269e150> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d19269e1 class=n-a></a><h2 class=main-title id=d19519>Grant information</h2><p>This work was supported in part by the Intramural Research Program of the National Institutes of Health (NIH) National Cancer Institute (NCI) (K.S.L. and T.R.B).</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d19269e874 class=n-a></a><h2 class=main-title id=d19269e876>Acknowledgements</h2><p class="" id=d19269e879>We are grateful to our past and present colleagues for stimulating discussions and sharing insights. We apologize to all authors whose work could not be cited owing to space limitations.</p></div><div class=back-section><a name=d19269e883 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d19787>References</h2><div class="section ref-list"><a name=d19269e883 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d19269e890 class=n-a></a>Dumontet C, Jordan MA: Microtubule-binding agents: a dynamic field of cancer therapeutics. <i>Nat Rev Drug Discov.</i> 2010; <b>9</b>(10): 790–803. <a target=xrefwindow id=d19269e898 href="http://www.ncbi.nlm.nih.gov/pubmed/20885410">PubMed Abstract </a> | <a target=xrefwindow id=d19269e901 href="http://dx.doi.org/10.1038/nrd3253">Publisher Full Text </a> | <a target=xrefwindow id=d19269e904 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3194401">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d19269e913 class=n-a></a>Strebhardt K: Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. <i>Nat Rev Drug Discov.</i> 2010; <b>9</b>(8): 643–60. <a target=xrefwindow id=d19269e921 href="http://www.ncbi.nlm.nih.gov/pubmed/20671765">PubMed Abstract </a> | <a target=xrefwindow id=d19269e924 href="http://dx.doi.org/10.1038/nrd3184">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d19269e933 class=n-a></a>Keen N, Taylor S: Aurora-kinase inhibitors as anticancer agents. <i>Nat Rev Cancer.</i> 2004; <b>4</b>(12): 927–36. <a target=xrefwindow id=d19269e941 href="http://www.ncbi.nlm.nih.gov/pubmed/15573114">PubMed Abstract </a> | <a target=xrefwindow id=d19269e944 href="http://dx.doi.org/10.1038/nrc1502">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d19269e953 class=n-a></a>Wood KW, Sakowicz R, Goldstein LS, <i> et al.</i>: CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. <i>Cell.</i> 1997; <b>91</b>(3): 357–66. <a target=xrefwindow id=d19269e964 href="http://www.ncbi.nlm.nih.gov/pubmed/9363944">PubMed Abstract </a> | <a target=xrefwindow id=d19269e967 href="http://dx.doi.org/10.1016/S0092-8674(00)80419-5">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d19269e976 class=n-a></a>Yen TJ, Li G, Schaar BT, <i> et al.</i>: CENP-E is a putative kinetochore motor that accumulates just before mitosis. <i>Nature.</i> 1992; <b>359</b>(6395): 536–9. <a target=xrefwindow id=d19269e987 href="http://www.ncbi.nlm.nih.gov/pubmed/1406971">PubMed Abstract </a> | <a target=xrefwindow id=d19269e990 href="http://dx.doi.org/10.1038/359536a0">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d19269e1000 class=n-a></a>Blangy A, Lane HA, d'Herin P, <i> et al.</i>: Phosphorylation by p34<sup><i>cdc2</i></sup> regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation <i>in vivo</i>. <i>Cell.</i> 1995; <b>83</b>(7): 1159–69. <a target=xrefwindow id=d19269e1019 href="http://www.ncbi.nlm.nih.gov/pubmed/8548803">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1022 href="http://dx.doi.org/10.1016/0092-8674(95)90142-6">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726094996"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1031 class=n-a></a>Matt S, Hofmann TG: The DNA damage-induced cell death response: a roadmap to kill cancer cells. <i>Cell Mol Life Sci.</i> 2016; <b>73</b>(15): 2829–50. <a target=xrefwindow id=d19269e1039 href="http://www.ncbi.nlm.nih.gov/pubmed/26791483">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1042 href="http://dx.doi.org/10.1007/s00018-016-2130-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726094996">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725321078"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1055 class=n-a></a>Sivakumar S, Gorbsky GJ: Spatiotemporal regulation of the anaphase-promoting complex in mitosis. <i>Nat Rev Mol Cell Biol.</i> 2015; <b>16</b>(2): 82–94. <a target=xrefwindow id=d19269e1063 href="http://www.ncbi.nlm.nih.gov/pubmed/25604195">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1066 href="http://dx.doi.org/10.1038/nrm3934">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1069 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4386896">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725321078">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727237790"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1082 class=n-a></a>Manasanch EE, Orlowski RZ: Proteasome inhibitors in cancer therapy. <i>Nat Rev Clin Oncol.</i> 2017; <b>14</b>(7): 417–433. <a target=xrefwindow id=d19269e1090 href="http://www.ncbi.nlm.nih.gov/pubmed/28117417">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1093 href="http://dx.doi.org/10.1038/nrclinonc.2016.206">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727237790">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725326442"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1106 class=n-a></a>Archambault V, Lépine G, Kachaner D: Understanding the Polo Kinase machine. <i>Oncogene.</i> 2015; <b>34</b>(37): 4799–807. <a target=xrefwindow id=d19269e1114 href="http://www.ncbi.nlm.nih.gov/pubmed/25619835">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1117 href="http://dx.doi.org/10.1038/onc.2014.451">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725326442">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d19269e1130 class=n-a></a>Park JE, Erikson RL, Lee KS: Feed-forward mechanism of converting biochemical cooperativity to mitotic processes at the kinetochore plate. <i>Proc Natl Acad Sci U S A.</i> 2011; <b>108</b>(20): 8200–5. <a target=xrefwindow id=d19269e1138 href="http://www.ncbi.nlm.nih.gov/pubmed/21525413">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1141 href="http://dx.doi.org/10.1073/pnas.1102020108">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1144 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3100994">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d19269e1154 class=n-a></a>Holtrich U, Wolf G, Bräuninger A, <i> et al.</i>: Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. <i>Proc Natl Acad Sci U S A.</i> 1994; <b>91</b>(5): 1736–40. <a target=xrefwindow id=d19269e1165 href="http://www.ncbi.nlm.nih.gov/pubmed/8127874">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1168 href="http://dx.doi.org/10.1073/pnas.91.5.1736">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1172 href="http://www.ncbi.nlm.nih.gov/pmc/articles/43238">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d19269e1181 class=n-a></a>Eckerdt F, Yuan J, Strebhardt K: Polo-like kinases and oncogenesis. <i>Oncogene.</i> 2005; <b>24</b>(2): 267–76. <a target=xrefwindow id=d19269e1189 href="http://www.ncbi.nlm.nih.gov/pubmed/15640842">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1192 href="http://dx.doi.org/10.1038/sj.onc.1208273">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d19269e1201 class=n-a></a>Takai N, Hamanaka R, Yoshimatsu J, <i> et al.</i>: Polo-like kinases (Plks) and cancer. <i>Oncogene.</i> 2005; <b>24</b>(2): 287–91. <a target=xrefwindow id=d19269e1212 href="http://www.ncbi.nlm.nih.gov/pubmed/15640844">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1215 href="http://dx.doi.org/10.1038/sj.onc.1208272">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d19269e1224 class=n-a></a>Cholewa BD, Liu X, Ahmad N: The role of polo-like kinase 1 in carcinogenesis: cause or consequence? <i>Cancer Res.</i> 2013; <b>73</b>(23): 6848–55. <a target=xrefwindow id=d19269e1232 href="http://www.ncbi.nlm.nih.gov/pubmed/24265276">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1235 href="http://dx.doi.org/10.1158/0008-5472.CAN-13-2197">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1238 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3849226">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d19269e1247 class=n-a></a>Wolf G, Elez R, Doermer A, <i> et al.</i>: Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. <i>Oncogene.</i> 1997; <b>14</b>(5): 543–9. <a target=xrefwindow id=d19269e1258 href="http://www.ncbi.nlm.nih.gov/pubmed/9053852">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1261 href="http://dx.doi.org/10.1038/sj.onc.1200862">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d19269e1270 class=n-a></a>Knecht R, Elez R, Oechler M, <i> et al.</i>: Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. <i>Cancer Res.</i> 1999; <b>59</b>(12): 2794–7. <a target=xrefwindow id=d19269e1281 href="http://www.ncbi.nlm.nih.gov/pubmed/10383133">PubMed Abstract </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1161208"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1291 class=n-a></a>Luo J, Emanuele MJ, Li D, <i> et al.</i>: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. <i>Cell.</i> 2009; <b>137</b>(5): 835–48. <a target=xrefwindow id=d19269e1302 href="http://www.ncbi.nlm.nih.gov/pubmed/19490893">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1305 href="http://dx.doi.org/10.1016/j.cell.2009.05.006">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1309 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2768667">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1161208">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/6885956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1322 class=n-a></a>Sur S, Pagliarini R, Bunz F, <i> et al.</i>: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. <i>Proc Natl Acad Sci U S A.</i> 2009; <b>106</b>(10): 3964–9. <a target=xrefwindow id=d19269e1333 href="http://www.ncbi.nlm.nih.gov/pubmed/19225112">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1336 href="http://dx.doi.org/10.1073/pnas.0813333106">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1340 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2656188">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/6885956">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d19269e1353 class=n-a></a>Park JE, Kim TS, Kim BY, <i> et al.</i>: Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain. <i>Cell Cycle.</i> 2015; <b>14</b>(22): 3624–34. <a target=xrefwindow id=d19269e1364 href="http://www.ncbi.nlm.nih.gov/pubmed/26513691">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1367 href="http://dx.doi.org/10.1080/15384101.2015.1104435">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1371 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4825759">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d19269e1380 class=n-a></a>Weinstein IB: Cancer. Addiction to oncogenes--the Achilles heal of cancer. <i>Science.</i> 2002; <b>297</b>(5578): 63–4. <a target=xrefwindow id=d19269e1388 href="http://www.ncbi.nlm.nih.gov/pubmed/12098689">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1391 href="http://dx.doi.org/10.1126/science.1073096">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1115584"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1400 class=n-a></a>McMurray HR, Sampson ER, Compitello G, <i> et al.</i>: Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. <i>Nature.</i> 2008; <b>453</b>(7198): 1112–6. <a target=xrefwindow id=d19269e1411 href="http://www.ncbi.nlm.nih.gov/pubmed/18500333">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1414 href="http://dx.doi.org/10.1038/nature06973">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1418 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2613942">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1115584">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d19269e1431 class=n-a></a>Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. <i>Cell.</i> 2009; <b>136</b>(5): 823–37. <a target=xrefwindow id=d19269e1439 href="http://www.ncbi.nlm.nih.gov/pubmed/19269363">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1442 href="http://dx.doi.org/10.1016/j.cell.2009.02.024">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1445 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2894612">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d19269e1455 class=n-a></a>Lee KS, Burke TR Jr, Park JE, <i> et al.</i>: Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. <i>Trends Pharmacol Sci.</i> 2015; <b>36</b>(12): 858–77. <a target=xrefwindow id=d19269e1466 href="http://www.ncbi.nlm.nih.gov/pubmed/26478211">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1469 href="http://dx.doi.org/10.1016/j.tips.2015.08.013">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1473 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4684765">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d19269e1482 class=n-a></a>Rudolph D, Steegmaier M, Hoffmann M, <i> et al.</i>: BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. <i>Clin Cancer Res.</i> 2009; <b>15</b>(9): 3094–102. <a target=xrefwindow id=d19269e1493 href="http://www.ncbi.nlm.nih.gov/pubmed/19383823">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1496 href="http://dx.doi.org/10.1158/1078-0432.CCR-08-2445">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727729290"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1505 class=n-a></a>Awada A, Dumez H, Aftimos PG, <i> et al.</i>: Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity. <i>Invest New Drugs.</i> 2015; <b>33</b>(3): 611–20. <a target=xrefwindow id=d19269e1516 href="http://www.ncbi.nlm.nih.gov/pubmed/25794535">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1519 href="http://dx.doi.org/10.1007/s10637-015-0223-9">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1523 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4435638">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727729290">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d19269e1536 class=n-a></a>Schöffski P, Awada A, Dumez H, <i> et al.</i>: A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. <i>Eur J Cancer.</i> 2012; <b>48</b>(2): 179–86. <a target=xrefwindow id=d19269e1547 href="http://www.ncbi.nlm.nih.gov/pubmed/22119200">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1550 href="http://dx.doi.org/10.1016/j.ejca.2011.11.001">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d19269e1559 class=n-a></a>Willemze R, Suciu S, Meloni G, <i> et al.</i>: High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. <i>J Clin Oncol.</i> 2014; <b>32</b>(3): 219–28. <a target=xrefwindow id=d19269e1570 href="http://www.ncbi.nlm.nih.gov/pubmed/24297940">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1573 href="http://dx.doi.org/10.1200/JCO.2013.51.8571">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d19269e1582 class=n-a></a>Döhner H, Lübbert M, Fiedler W, <i> et al.</i>: Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. <i>Blood.</i> 2014; <b>124</b>(9): 1426–33. <a target=xrefwindow id=d19269e1593 href="http://www.ncbi.nlm.nih.gov/pubmed/25006120">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1596 href="http://dx.doi.org/10.1182/blood-2014-03-560557">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1600 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4148765">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718494309"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1610 class=n-a></a>Gjertsen BT, Schöffski P: Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. <i>Leukemia.</i> 2015; <b>29</b>(1): 11–9. <a target=xrefwindow id=d19269e1618 href="http://www.ncbi.nlm.nih.gov/pubmed/25027517">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1621 href="http://dx.doi.org/10.1038/leu.2014.222">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1624 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4335352">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718494309">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d19269e1637 class=n-a></a>Olmos D, Barker D, Sharma R, <i> et al.</i>: Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. <i>Clin Cancer Res.</i> 2011; <b>17</b>(10): 3420–30. <a target=xrefwindow id=d19269e1648 href="http://www.ncbi.nlm.nih.gov/pubmed/21459796">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1651 href="http://dx.doi.org/10.1158/1078-0432.CCR-10-2946">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d19269e1660 class=n-a></a>Duffey MO, Vos TJ, Adams R, <i> et al.</i>: Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905). <i>J Med Chem.</i> 2012; <b>55</b>(1): 197–208. <a target=xrefwindow id=d19269e1671 href="http://www.ncbi.nlm.nih.gov/pubmed/22070629">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1674 href="http://dx.doi.org/10.1021/jm2011172">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d19269e1683 class=n-a></a>Shi JQ, Lasky K, Shinde V, <i> et al.</i>: MLN0905, a small-molecule <i>plk1</i> inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. <i>Mol Cancer Ther.</i> 2012; <b>11</b>(9): 2045–53. <a target=xrefwindow id=d19269e1697 href="http://www.ncbi.nlm.nih.gov/pubmed/22609854">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1701 href="http://dx.doi.org/10.1158/1535-7163.MCT-11-1036">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d19269e1710 class=n-a></a>Chen S, Bartkovitz D, Cai J, <i> et al.</i>: Identification of novel, potent and selective inhibitors of Polo-like kinase 1. <i>Bioorg Med Chem Lett.</i> 2012; <b>22</b>(2): 1247–50. <a target=xrefwindow id=d19269e1721 href="http://www.ncbi.nlm.nih.gov/pubmed/22172702">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1724 href="http://dx.doi.org/10.1016/j.bmcl.2011.11.052">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725310298"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1733 class=n-a></a>Wang NN, Li ZH, Zhao H, <i> et al.</i>: Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells. <i>Int J Mol Sci.</i> 2015; <b>16</b>(1): 1266–92. <a target=xrefwindow id=d19269e1744 href="http://www.ncbi.nlm.nih.gov/pubmed/25574601">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1747 href="http://dx.doi.org/10.3390/ijms16011266">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1751 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4307303">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725310298">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d19269e1765 class=n-a></a>Beria I, Bossi RT, Brasca MG, <i> et al.</i>: NMS-P937, a 4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. <i>Bioorg Med Chem Lett.</i> 2011; <b>21</b>(10): 2969–74. <a target=xrefwindow id=d19269e1783 href="http://www.ncbi.nlm.nih.gov/pubmed/21470862">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1786 href="http://dx.doi.org/10.1016/j.bmcl.2011.03.054">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d19269e1795 class=n-a></a>Valsasina B, Beria I, Alli C, <i> et al.</i>: NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. <i>Mol Cancer Ther.</i> 2012; <b>11</b>(4): 1006–16. <a target=xrefwindow id=d19269e1806 href="http://www.ncbi.nlm.nih.gov/pubmed/22319201">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1809 href="http://dx.doi.org/10.1158/1535-7163.MCT-11-0765">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d19269e1818 class=n-a></a>Hikichi Y, Honda K, Hikami K, <i> et al.</i>: TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. <i>Mol Cancer Ther.</i> 2012; <b>11</b>(3): 700–9. <a target=xrefwindow id=d19269e1829 href="http://www.ncbi.nlm.nih.gov/pubmed/22188812">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1832 href="http://dx.doi.org/10.1158/1535-7163.MCT-11-0762">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1102108"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1841 class=n-a></a>Karaman MW, Herrgard S, Treiber DK, <i> et al.</i>: A quantitative analysis of kinase inhibitor selectivity. <i>Nat Biotechnol.</i> 2008; <b>26</b>(1): 127–32. <a target=xrefwindow id=d19269e1852 href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1855 href="http://dx.doi.org/10.1038/nbt1358">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1102108">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d19269e1868 class=n-a></a>Syed N, Smith P, Sullivan A, <i> et al.</i>: Transcriptional silencing of Polo-like kinase 2 <i>(SNK/PLK2)</i> is a frequent event in B-cell malignancies. <i>Blood.</i> 2006; <b>107</b>(1): 250–6. <a target=xrefwindow id=d19269e1882 href="http://www.ncbi.nlm.nih.gov/pubmed/16160013">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1886 href="http://dx.doi.org/10.1182/blood-2005-03-1194">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d19269e1895 class=n-a></a>Yang Y, Bai J, Shen R, <i> et al.</i>: Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. <i>Cancer Res.</i> 2008; <b>68</b>(11): 4077–85. <a target=xrefwindow id=d19269e1906 href="http://www.ncbi.nlm.nih.gov/pubmed/18519666">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1909 href="http://dx.doi.org/10.1158/0008-5472.CAN-07-6182">Publisher Full Text </a> | <a target=xrefwindow id=d19269e1913 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3725591">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1066069"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e1923 class=n-a></a>Lénárt P, Petronczki M, Steegmaier M, <i> et al.</i>: The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. <i>Curr Biol.</i> 2007; <b>17</b>(4): 304–15. <a target=xrefwindow id=d19269e1934 href="http://www.ncbi.nlm.nih.gov/pubmed/17291761">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1937 href="http://dx.doi.org/10.1016/j.cub.2006.12.046">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1066069">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d19269e1950 class=n-a></a>Steegmaier M, Hoffmann M, Baum A, <i> et al.</i>: BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth <i>in vivo</i>. <i>Curr Biol.</i> 2007; <b>17</b>(4): 316–22. <a target=xrefwindow id=d19269e1964 href="http://www.ncbi.nlm.nih.gov/pubmed/17291758">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1968 href="http://dx.doi.org/10.1016/j.cub.2006.12.037">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d19269e1977 class=n-a></a>Aubele DL, Hom RK, Adler M, <i> et al.</i>: Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain. <i>ChemMedChem.</i> 2013; <b>8</b>(8): 1295–313. <a target=xrefwindow id=d19269e1988 href="http://www.ncbi.nlm.nih.gov/pubmed/23794260">PubMed Abstract </a> | <a target=xrefwindow id=d19269e1991 href="http://dx.doi.org/10.1002/cmdc.201300166">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d19269e2000 class=n-a></a>Keppner S, Proschak E, Schneider G, <i> et al.</i>: Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. <i>ChemMedChem.</i> 2009; <b>4</b>(11): 1806–9. <a target=xrefwindow id=d19269e2011 href="http://www.ncbi.nlm.nih.gov/pubmed/19746360">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2014 href="http://dx.doi.org/10.1002/cmdc.200900338">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d19269e2023 class=n-a></a>Keppner S, Proschak E, Kaufmann M, <i> et al.</i>: Biological impact of freezing Plk1 in its inactive conformation in cancer cells. <i>Cell Cycle.</i> 2010; <b>9</b>(4): 761–73. <a target=xrefwindow id=d19269e2034 href="http://www.ncbi.nlm.nih.gov/pubmed/20139717">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2037 href="http://dx.doi.org/10.4161/cc.9.4.10644">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d19269e2046 class=n-a></a>Liu Y, Gray NS: Rational design of inhibitors that bind to inactive kinase conformations. <i>Nat Chem Biol.</i> 2006; <b>2</b>(7): 358–64. <a target=xrefwindow id=d19269e2054 href="http://www.ncbi.nlm.nih.gov/pubmed/16783341">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2057 href="http://dx.doi.org/10.1038/nchembio799">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d19269e2067 class=n-a></a>Yang W, Chen Y, Zhou X, <i> et al.</i>: Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors. <i>Eur J Med Chem.</i> 2015; <b>89</b>: 581–96. <a target=xrefwindow id=d19269e2078 href="http://www.ncbi.nlm.nih.gov/pubmed/25462267">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2081 href="http://dx.doi.org/10.1016/j.ejmech.2014.10.039">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d19269e2090 class=n-a></a>Dietrich J, Gokhale V, Wang X, <i> et al.</i>: Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors. <i>Bioorg Med Chem.</i> 2010; <b>18</b>(1): 292–304. <a target=xrefwindow id=d19269e2101 href="http://www.ncbi.nlm.nih.gov/pubmed/19962319">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2104 href="http://dx.doi.org/10.1016/j.bmc.2009.10.055">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1024981"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e2113 class=n-a></a>Gumireddy K, Reddy MV, Cosenza SC, <i> et al.</i>: ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. <i>Cancer Cell.</i> 2005; <b>7</b>(3): 275–86. <a target=xrefwindow id=d19269e2124 href="http://www.ncbi.nlm.nih.gov/pubmed/15766665">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2127 href="http://dx.doi.org/10.1016/j.ccr.2005.02.009">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1024981">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d19269e2140 class=n-a></a>Bowles DW, Diamond JR, Lam ET, <i> et al.</i>: Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. <i>Clin Cancer Res.</i> 2014; <b>20</b>(6): 1656–65. <a target=xrefwindow id=d19269e2151 href="http://www.ncbi.nlm.nih.gov/pubmed/24493827">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2154 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-2506">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2158 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4160109">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d19269e2167 class=n-a></a>Reddy MV, Venkatapuram P, Mallireddigari MR, <i> et al.</i>: Discovery of a clinical stage multi-kinase inhibitor sodium (<i>E</i>)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. <i>J Med Chem.</i> 2011; <b>54</b>(18): 6254–76. <a target=xrefwindow id=d19269e2181 href="http://www.ncbi.nlm.nih.gov/pubmed/21812421">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2185 href="http://dx.doi.org/10.1021/jm200570p">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2188 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4503467">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d19269e2197 class=n-a></a>Peters U, Cherian J, Kim JH, <i> et al.</i>: Probing cell-division phenotype space and Polo-like kinase function using small molecules. <i>Nat Chem Biol.</i> 2006; <b>2</b>(11): 618–26. <a target=xrefwindow id=d19269e2208 href="http://www.ncbi.nlm.nih.gov/pubmed/17028580">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2211 href="http://dx.doi.org/10.1038/nchembio826">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d19269e2221 class=n-a></a>Park JE, Soung NK, Johmura Y, <i> et al.</i>: Polo-box domain: a versatile mediator of polo-like kinase function. <i>Cell Mol Life Sci.</i> 2010; <b>67</b>(12): 1957–70. <a target=xrefwindow id=d19269e2232 href="http://www.ncbi.nlm.nih.gov/pubmed/20148280">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2235 href="http://dx.doi.org/10.1007/s00018-010-0279-9">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2239 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2877763">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1163113"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e2248 class=n-a></a>Yun SM, Moulaei T, Lim D, <i> et al.</i>: Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. <i>Nat Struct Mol Biol.</i> 2009; <b>16</b>(8): 876–82. <a target=xrefwindow id=d19269e2259 href="http://www.ncbi.nlm.nih.gov/pubmed/19597481">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2262 href="http://dx.doi.org/10.1038/nsmb.1628">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2266 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2721907">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1163113">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d19269e2279 class=n-a></a>Liu F, Park JE, Qian WJ, <i> et al.</i>: Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. <i>Nat Chem Biol.</i> 2011; <b>7</b>(9): 595–601. <a target=xrefwindow id=d19269e2290 href="http://www.ncbi.nlm.nih.gov/pubmed/21765407">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2293 href="http://dx.doi.org/10.1038/nchembio.614">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2297 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3158281">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d19269e2306 class=n-a></a>Liu F, Park JE, Qian WJ, <i> et al.</i>: Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. <i>ACS Chem Biol.</i> 2012; <b>7</b>(5): 805–10. <a target=xrefwindow id=d19269e2317 href="http://www.ncbi.nlm.nih.gov/pubmed/22292814">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2320 href="http://dx.doi.org/10.1021/cb200469a">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2324 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3355227">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d19269e2333 class=n-a></a>Liu F, Park JE, Qian WJ, <i> et al.</i>: Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1. <i>Chembiochem.</i> 2012; <b>13</b>(9): 1291–6. <a target=xrefwindow id=d19269e2344 href="http://www.ncbi.nlm.nih.gov/pubmed/22570300">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2347 href="http://dx.doi.org/10.1002/cbic.201200206">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2351 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4536914">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d19269e2360 class=n-a></a>Qian W, Park JE, Liu F, <i> et al.</i>: Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position. <i>Bioorg Med Chem.</i> 2013; <b>21</b>(14): 3996–4003. <a target=xrefwindow id=d19269e2371 href="http://www.ncbi.nlm.nih.gov/pubmed/22743087">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2374 href="http://dx.doi.org/10.1016/j.bmc.2012.05.036">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2378 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3462889">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d19269e2388 class=n-a></a>Qian WJ, Park JE, Lim D, <i> et al.</i>: Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells. <i>Biopolymers.</i> 2014; <b>102</b>(6): 444–55. <a target=xrefwindow id=d19269e2399 href="http://www.ncbi.nlm.nih.gov/pubmed/25283071">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2402 href="http://dx.doi.org/10.1002/bip.22569">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2406 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4895914">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d19269e2415 class=n-a></a>Murugan RN, Park JE, Lim D, <i> et al.</i>: Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1. <i>Bioorg Med Chem.</i> 2013; <b>21</b>(9): 2623–34. <a target=xrefwindow id=d19269e2426 href="http://www.ncbi.nlm.nih.gov/pubmed/23498919">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2429 href="http://dx.doi.org/10.1016/j.bmc.2013.02.020">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d19269e2438 class=n-a></a>Qian WJ, Park JE, Grant R, <i> et al.</i>: Neighbor-directed histidine N (τ)-alkylation: A route to imidazolium-containing phosphopeptide macrocycles. <i>Biopolymers.</i> 2015; <b>104</b>(6): 663–73. <a target=xrefwindow id=d19269e2449 href="http://www.ncbi.nlm.nih.gov/pubmed/26152807">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2452 href="http://dx.doi.org/10.1002/bip.22698">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2456 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4865893">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d19269e2465 class=n-a></a>Ahn M, Han YH, Park JE, <i> et al.</i>: A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1. <i>J Med Chem.</i> 2015; <b>58</b>(1): 294–304. <a target=xrefwindow id=d19269e2476 href="http://www.ncbi.nlm.nih.gov/pubmed/25347203">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2479 href="http://dx.doi.org/10.1021/jm501147g">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1108689"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e2488 class=n-a></a>Reindl W, Yuan J, Krämer A, <i> et al.</i>: Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. <i>Chem Biol.</i> 2008; <b>15</b>(5): 459–66. <a target=xrefwindow id=d19269e2499 href="http://www.ncbi.nlm.nih.gov/pubmed/18482698">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2502 href="http://dx.doi.org/10.1016/j.chembiol.2008.03.013">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1108689">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d19269e2515 class=n-a></a>Reindl W, Yuan J, Krämer A, <i> et al.</i>: A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. <i>Chembiochem.</i> 2009; <b>10</b>(7): 1145–8. <a target=xrefwindow id=d19269e2526 href="http://www.ncbi.nlm.nih.gov/pubmed/19350612">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2529 href="http://dx.doi.org/10.1002/cbic.200900059">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1147354"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d19269e2539 class=n-a></a>Watanabe N, Sekine T, Takagi M: Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. <i>J Biol Chem.</i> 2009; <b>284</b>(4): 2344–53. <a target=xrefwindow id=d19269e2547 href="http://www.ncbi.nlm.nih.gov/pubmed/19033445">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2550 href="http://dx.doi.org/10.1074/jbc.M805308200">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1147354">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d19269e2563 class=n-a></a>Chen Y, Zhang J, Li D, <i> et al.</i>: Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. <i>Oncotarget.</i> 2017; <b>8</b>(1): 1234–46. <a target=xrefwindow id=d19269e2574 href="http://www.ncbi.nlm.nih.gov/pubmed/27902479">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2577 href="http://dx.doi.org/10.18632/oncotarget.13603">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2581 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5352051">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d19269e2590 class=n-a></a>Normandin K, Lavallée JF, Futter M, <i> et al.</i>: Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay. <i>Sci Rep.</i> 2016; <b>5</b>: 37581. <a target=xrefwindow id=d19269e2601 href="http://www.ncbi.nlm.nih.gov/pubmed/27874094">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2604 href="http://dx.doi.org/10.1038/srep37581">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2608 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5118709">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d19269e2617 class=n-a></a>Shan HM, Shi Y, Quan J: Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. <i>ChemMedChem.</i> 2015; <b>10</b>(1): 158–63. <a target=xrefwindow id=d19269e2625 href="http://www.ncbi.nlm.nih.gov/pubmed/25196850">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2628 href="http://dx.doi.org/10.1002/cmdc.201402284">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d19269e2637 class=n-a></a>Yin Z, Song Y, Rehse PH: Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. <i>ACS Chem Biol.</i> 2013; <b>8</b>(2): 303–8. <a target=xrefwindow id=d19269e2645 href="http://www.ncbi.nlm.nih.gov/pubmed/23135290">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2648 href="http://dx.doi.org/10.1021/cb3004379">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d19269e2657 class=n-a></a>Lee KS, Idle JR: Pinning down the polo-box domain. <i>Chem Biol.</i> 2008; <b>15</b>(5): 415–6. <a target=xrefwindow id=d19269e2665 href="http://www.ncbi.nlm.nih.gov/pubmed/18482691">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2668 href="http://dx.doi.org/10.1016/j.chembiol.2008.04.009">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d19269e2678 class=n-a></a>Liao C, Park JE, Bang JK, <i> et al.</i>: Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. <i>ACS Med Chem Lett.</i> 2010; <b>1</b>(3): 110–4. <a target=xrefwindow id=d19269e2689 href="http://www.ncbi.nlm.nih.gov/pubmed/20625469">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2692 href="http://dx.doi.org/10.1021/ml100020e">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2696 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2898210">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d19269e2705 class=n-a></a>Aldrich C, Bertozzi C, Georg GI, <i> et al.</i>: The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Cent Sci.</i> 2017; <b>3</b>(3): 143–7. <a target=xrefwindow id=d19269e2716 href="http://www.ncbi.nlm.nih.gov/pubmed/28386587">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2719 href="http://dx.doi.org/10.1021/acscentsci.7b00069">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2723 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5364449">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d19269e2732 class=n-a></a>Archambault V, Normandin K: Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators. <i>Cell Cycle.</i> 2017; 1–5. <a target=xrefwindow id=d19269e2737 href="http://www.ncbi.nlm.nih.gov/pubmed/28521657">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2740 href="http://dx.doi.org/10.1080/15384101.2017.1325043">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d19269e2749 class=n-a></a>Hymel D, Burke TR Jr: Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1. <i>ChemMedChem.</i> 2017; <b>12</b>(3): 202–6. <a target=xrefwindow id=d19269e2757 href="http://www.ncbi.nlm.nih.gov/pubmed/27992122">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2760 href="http://dx.doi.org/10.1002/cmdc.201600574">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2763 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5340193">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d19269e2772 class=n-a></a>Zhao XZ, Hymel D, Burke TR Jr: Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain. <i>Bioorg Med Chem Lett.</i> 2016; <b>26</b>(20): 5009–12. <a target=xrefwindow id=d19269e2780 href="http://www.ncbi.nlm.nih.gov/pubmed/27624074">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2783 href="http://dx.doi.org/10.1016/j.bmcl.2016.08.098">Publisher Full Text </a> | <a target=xrefwindow id=d19269e2786 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5061138">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d19269e2795 class=n-a></a>Zhao XZ, Hymel D, Burke TR Jr: Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides. <i>Bioorg Med Chem.</i> 2017; pii: S0968-0896(17)30170-0. <a target=xrefwindow id=d19269e2800 href="http://www.ncbi.nlm.nih.gov/pubmed/28285924">PubMed Abstract </a> | <a target=xrefwindow id=d19269e2803 href="http://dx.doi.org/10.1016/j.bmc.2017.02.063">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Jun 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1024.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1024.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA<br/> <sup>2</sup> Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, 21702, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-1024/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 29 Jun 2017, 6:1024 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11398.1">https://doi.org/10.12688/f1000research.11398.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Park JE <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12303 data-id=11398 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11398.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-1024/v1/pdf?article_uuid=aa983cb4-792d-408a-8467-383ca18cb772" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11398.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Park JE, Hymel D, Burke, Jr. TR and Lee KS. Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents [version 1; peer review: 4 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1024 (<a href="https://doi.org/10.12688/f1000research.11398.1" target=_blank>https://doi.org/10.12688/f1000research.11398.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11398 id=mobile-track-article-signin-11398 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11398?target=/articles/6-1024.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12303 /> <input name=articleId type=hidden value=11398 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Xiaoqi Liu</strong>, Department of Biochemistry, Purdue University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Taebo Sim</strong>, Chemical Kinomics Research Center, Korea Institute of Science and Technology, South Korea </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Vincent Archambault</strong>, Université de Montréal, Canada </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Wei Dai</strong>, New York University School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Jun 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1024.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1024.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=21914-21821></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=21918-23909></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=21916-23910></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=21917-23911></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=4><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> <th class="c-report-timeline__headings-version p-article__color--dark">4</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-1024/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>29 Jun 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Xiaoqi Liu</strong>, Department of Biochemistry, Purdue University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Taebo Sim</strong>, Chemical Kinomics Research Center, Korea Institute of Science and Technology, South Korea </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Vincent Archambault</strong>, Université de Montréal, Canada </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Wei Dai</strong>, New York University School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-1024.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-1024/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Current progress and future perspectives...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-1024/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-1024/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-1024/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Park JE et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-1024/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-1024",
            templates : {
                twitter : "Current progress and future perspectives in the development of.... Park JE et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-1024/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11398/12303")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12303");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "23909": 0,
                           "23910": 0,
                           "23911": 0,
                           "21821": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "7d0b093d-ee85-4e03-b087-67df4ecad967";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1024.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1024.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1024.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-1024.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-1024.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>